BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8952157)

  • 1. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
    Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
    Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
    Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
    Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
    González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
    Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
    Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
    Rodríguez JN; Martino ML; Diéguez JC; Prados D
    Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recombinant human erythropoietin in anemia associated with pediatric cancer: study of the identification of predictors of response].
    León Molinari P; Jiménez Monteagudo M; Barona Zamora P; Riol Diego M; Castro Paz L; Sierrasesúmaga Ariznavarreta L
    An Esp Pediatr; 1998 Jul; 49(1):17-22. PubMed ID: 9718761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
    Beguin Y
    Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
    Katodritou E; Terpos E; Zervas K; Speletas M; Kapetanos D; Kartsios C; Verrou E; Banti A; Effraimidou S; Christakis J
    Ann Hematol; 2007 May; 86(5):369-76. PubMed ID: 17375302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
    Nowrousian MR
    Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
    Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
    Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
    Gasche C; Waldhoer T; Feichtenschlager T; Male C; Mayer A; Mittermaier C; Petritsch W;
    Am J Gastroenterol; 2001 Aug; 96(8):2382-7. PubMed ID: 11513178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
    Baron F; Frère P; Fillet G; Beguin Y
    Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment.
    Adamson JW; Spivak JL
    Surgery; 1994 Jan; 115(1):7-15. PubMed ID: 8284765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
    Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
    Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma.
    Ludwig H; Pecherstorfer M; Leitgeb C; Fritz E
    Stem Cells; 1993 Sep; 11(5):348-55. PubMed ID: 8241947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.